{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:31Z","timestamp":1767135151388,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":50,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010693.pub2","type":"reference-entry","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T20:41:34Z","timestamp":1389127294000},"source":"Crossref","is-referenced-by-count":11,"title":["Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack"],"prefix":"10.1002","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"10.1002\/14651858.CD010693.pub2-BIB1|cit1","first-page":"195 (Abst.PO104","article-title":"Effects of pioglitazone in patients with impaired glucose tolerance after stroke; progress report from J-SPIRIT study","volume":"5","author":"Tanaka","year":"2010","journal-title":"International Journal of Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"Abst.ATP416","DOI":"10.1161\/str.44.suppl_1.ATP416","article-title":"Effects of pioglitazone in patients with abnormal glucose metabolism after stroke. The J-SPIRIT study","volume":"44","author":"Tanaka","year":"2013","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/01.STR.0000071108.00234.0E","article-title":"Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke","volume":"34","author":"Kernan","year":"2003","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.jacc.2006.01.073","article-title":"Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment","volume":"47","author":"Marfella","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB5|cit5","first-page":"286","article-title":"PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCI (Actos) therapy","volume":"16","author":"Anonymous","year":"2005","journal-title":"Cardiovascular Journal of South Africa"},{"key":"10.1002\/14651858.CD010693.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/diacare.27.7.1647","article-title":"The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)","volume":"27","author":"Charbonnel","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD010693.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","article-title":"Impact of peripheral arterial disease in patients with diabetes - results from PROactive (PROactive 11)","volume":"202","author":"Dormandy","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD010693.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010693.pub2-BIB9|cit9","first-page":"355","article-title":"PROactive 07: Pioglitazone in the treatment of type 2 diabetes: Results of the PROactive study","volume":"3","author":"Erdmann","year":"2007","journal-title":"Vascular Health and Risk Management"},{"key":"10.1002\/14651858.CD010693.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1753-0407.2010.00082.x","article-title":"Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)","volume":"2","author":"Erdmann","year":"2010","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD010693.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","article-title":"Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)","volume":"155","author":"Wilcox","year":"2008","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD010693.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1463-1326.2008.00959.x","article-title":"Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial","volume":"11","author":"Lundby Christensen","year":"2009","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD010693.pub2-BIB14|cit14","unstructured":"Dehnavi RA A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes Nederlands Trial Register (http:\/\/www.trialregister.nl) 2005"},{"key":"10.1002\/14651858.CD010693.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3132\/dvdr.2008.043","article-title":"Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk","volume":"5","author":"Forst","year":"2008","journal-title":"Diabetes and Vascular Disease Research"},{"key":"10.1002\/14651858.CD010693.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2796.2007.01767.x","article-title":"Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study","volume":"261","author":"Hedblad","year":"2007","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD010693.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jcem.86.7.7810","article-title":"Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"86","author":"Koshiyama","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD010693.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/01.ATV.0000203511.66681.7f","article-title":"Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial","volume":"26","author":"Meisner","year":"2006","journal-title":"Arteriosclerosis Thrombosis and Vascular Biology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/01.ATV.0000124890.40436.77","article-title":"Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients with diabetes mellitus","volume":"24","author":"Sidhu","year":"2004","journal-title":"Arteriosclerosis Thrombosis and Vascular Biology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2337\/dc05-2462","article-title":"Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes","volume":"29","author":"Hodis","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD010693.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-5491.2004.01353.x","article-title":"The association of smoking and subclinical atherosclerosis in type 2 diabetes: modification by duration of diabetes","volume":"22","author":"Karim","year":"2005","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD010693.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0021-9150(03)00291-0","article-title":"Time from diagnosis of type 2 diabetes to initiation of insulin therapy is related to carotid artery intima-media thickness","volume":"170","author":"Zheng","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD010693.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.amjcard.2006.10.061","article-title":"Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus","volume":"99","author":"Zheng","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB24|cit24","unstructured":"GlaxoSmithKline Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) ClinicalTrials.gov 2009"},{"key":"10.1002\/14651858.CD010693.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0197-2456(97)00151-7","article-title":"TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus","volume":"19","author":"Azen","year":"1998","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010693.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2007.10.016","article-title":"Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes","volume":"199","author":"Xiang","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD010693.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2004-1685","article-title":"Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes","volume":"90","author":"Xiang","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD010693.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1532-429X-11-24","article-title":"Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance","volume":"11","author":"Varghese","year":"2009","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"key":"10.1002\/14651858.CD010693.pub2-BIB29|cit29","unstructured":"Insulin Resistance Intervention After Stroke Trial (IRIS) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00091949"},{"key":"10.1002\/14651858.CD010693.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1476-5381.2010.00671.x","article-title":"Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation","volume":"160","author":"Collino","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010693.pub2-BIB31|cit31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004296.pub2","article-title":"Triflusal for preventing serious vascular events in people at high risk","author":"Costa","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010693.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/en.2008-1757","article-title":"Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db\/db mice","volume":"150","author":"Dasu","year":"2009","journal-title":"Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD010693.pub2-BIB33|cit33","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001820.pub3","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease","author":"Schryver","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD010693.pub2-BIB34|cit34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001342.pub3","article-title":"Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin","author":"Schryver","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010693.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010693.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000047756","article-title":"Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size","volume":"13","author":"Els","year":"2002","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD010693.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010693.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002018-200932030-00005","article-title":"Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study","volume":"32","author":"Fogg","year":"2009","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD010693.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1161\/01.STR.0000223048.70103.F1","article-title":"Primary prevention of ischemic stroke: a guideline from the American Heart Association\/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline","volume":"37","author":"Goldstein","year":"2006","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010693.pub2-BIB41|cit41","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010693.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1212\/WNL.48.4.891","article-title":"Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study","volume":"48","author":"J\u00f8rgensen","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tcm.2010.02.007","article-title":"Neuronal nitric oxide synthase and human vascular regulation","volume":"19","author":"Melikian","year":"2009","journal-title":"Trends in Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD010693.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00024677-200201010-00002","article-title":"The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus","volume":"1","author":"Mooradian","year":"2002","journal-title":"Treatments in Endocrinology"},{"key":"10.1002\/14651858.CD010693.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1161\/STROKEAHA.107.486522","article-title":"Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure","volume":"38","author":"Nakamura","year":"2007","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD010693.pub2-BIB46|cit46","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"2","key":"10.1002\/14651858.CD010693.pub2-BIB47|cit47","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000248.pub2","article-title":"Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack","author":"Sandercock","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010693.pub2-BIB48|cit48","first-page":"292","article-title":"Stroke","volume-title":"Clinical Neurology","author":"Simon","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD010693.pub2-BIB49|cit49","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001246.pub2","article-title":"Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients","author":"Sudlow","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010693.pub2-BIB50|cit50","unstructured":"World Health Organization The atlas of heart disease and stroke http:\/\/www.who.int\/cardiovascular_diseases\/resources\/atlas\/en"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010693.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010693.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:33:04Z","timestamp":1647880384000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010693.pub2"}},"subtitle":[],"editor":[{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010693.pub2","relation":{},"subject":[],"published":{"date-parts":[[2014,1,8]]}}}